Cai Geng-Xi, Kong Wei-Yao, Liu Yuan, Zhong Shu-Yi, Liu Qing, Deng Yuan-Fei, Ye Guo-Lin
Department of Breast Surgery, The First People's Hospital of Foshan, 528000, Foshan, Guangdong, China.
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, 511436, Guangzhou, Guangdong, China.
Cell Death Discov. 2023 Jul 1;9(1):211. doi: 10.1038/s41420-023-01525-8.
The translocation of biological macromolecules between cytoplasm and nucleus is of great significance to maintain various life processes in both normal and cancer cells. Disturbance of transport function likely leads to an unbalanced state between tumor suppressors and tumor-promoting factors. In this study, based on the unbiased analysis of protein expression differences with a mass spectrometer between human breast malignant tumors and benign hyperplastic tissues, we identified that Importin-7, a nuclear transport factor, is highly expressed in breast cancer (BC) and predicts poor outcomes. Further studies showed that Importin-7 promotes cell cycle progression and proliferation. Mechanistically, through co-immunoprecipitation, immunofluorescence, and nuclear-cytoplasmic protein separation experiments, we discovered that AR and USP22 can bind to Importin-7 as cargoes to promote BC progression. In addition, this study provides a rationale for a therapeutic strategy to restream the malignant progression of AR-positive BC by inhibiting the high expression state of Importin-7. Moreover, the knockdown of Importin-7 increased the responsiveness of BC cells to the AR signaling inhibitor, enzalutamide, suggesting that targeting Importin-7 may be a potential therapeutic strategy.
生物大分子在细胞质和细胞核之间的转运对于维持正常细胞和癌细胞中的各种生命过程具有重要意义。运输功能的紊乱可能导致肿瘤抑制因子和促肿瘤因子之间的失衡状态。在本研究中,基于对人乳腺恶性肿瘤和良性增生组织之间蛋白质表达差异进行的无偏质谱分析,我们发现核转运因子Importin-7在乳腺癌(BC)中高表达,并预示着不良预后。进一步研究表明,Importin-7促进细胞周期进程和增殖。从机制上讲,通过免疫共沉淀、免疫荧光和核质蛋白分离实验,我们发现雄激素受体(AR)和泛素特异性蛋白酶22(USP22)可以作为货物与Importin-7结合,从而促进BC进展。此外,本研究为通过抑制Importin-7的高表达状态来逆转AR阳性BC恶性进展的治疗策略提供了理论依据。而且,敲低Importin-7增加了BC细胞对AR信号抑制剂恩杂鲁胺的反应性,表明靶向Importin-7可能是一种潜在的治疗策略。